Ocelot Bio
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $36M
Investors
- 3
About Ocelot Bio
Based in California, US, and founded in 2020 by Geoff Harris, Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for patients with liver diseases. In March 2022, Ocelot Bio, Inc. As of March 2022, Katherine Vega Stultz is the President and CEO of Ocelot Bio, Inc. Ocelot Bio’s product line includes OCE-205, a therapeutic peptide that targets complications of ESLD-induced portal hypertension for patients with liver diseases like HRS-AKI. OCE-205 is under phase 2 clinical trial to evaluate its effectiveness in the treatment of HRS-AKI, a serious and life-threatening consequence of ESLD, that leads to acute renal failure and often death.
Who invested in Ocelot Bio
3 investors across 1 round
See all investors in Ocelot Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 15, 2021
Amount
$36M
Investors
Questions about Ocelot Bio
Who invested in Ocelot Bio?
Ocelot Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ocelot Bio raised?
Ocelot Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ocelot Bio last raise money?
Ocelot Bio's most recent round on record is a Series A, in Apr 2021.
What does Ocelot Bio do?
Based in California, US, and founded in 2020 by Geoff Harris, Ocelot Bio, Inc.
Where is Ocelot Bio headquartered?
Ocelot Bio is headquartered in San Diego, US.
Which VCs invest in companies like Ocelot Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ocelot Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ocelot Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.